Improved Outcomes Associated With Teduglutide Use in Patients With Both Short Bowel Syndrome and Crohn's Disease.

Rex K SiuChristian KarimeJana G HashashJami KinnucanMichael F PiccoFrancis A Farraye

Published in: Crohn's & colitis 360 (2024)

This retrospective case series demonstrated improved clinical outcomes in patients with CD-CIF and SBS treated with teduglutide resulting in decreased PS requirements, antidiarrheal medications requirement, and stool output without significant effects on immunosuppressive therapy.

Keyphrases

cross sectional
case report
type diabetes
newly diagnosed
mesenchymal stem cells
skeletal muscle
insulin resistance
cell therapy
chemotherapy induced